Literature DB >> 11795675

Henoch-Schönlein purpura nephritis: an update.

J C Davin1, J J Weening.   

Abstract

UNLABELLED: Henoch-Schönlein purpura (HSP) is a form of systemic vasculitis characterised by vascular wall deposits of predominally IgA typically involving small vessels in skin, gut and glomeruli and associated with purpura, colic, haematuria and arthralgia or arthritis. HSP nephritis (HSPN) leads to chronic renal failure in up to 20% of paediatric patients after 20 years of follow-up in selected series. The risk is related to the initial clinical presentation and the percentage of glomeruli presenting with epithelial crescents. The pathogenesis of HSPN might be related to an increased production of abnormally glycosylated IgA, which is not sufficiently cleared by the liver and leads to the formation of IgA macromolecules, accumulating in the circulation with subsequent deposition in vessel walls and in the glomerular mesangium. HSPN is related to IgA nephropathy. These two diseases can be encountered consecutively in the same patient, have been described in identical twins and bear similar pathological and biological abnormalities. No consensus about treatment has been reached up to now. Recent studies indicate that early treatment with methylprednisolone or a combination of steroids and cytotoxic drugs might prevent evolution to chronic renal failure.
CONCLUSION: Despite numerous studies, the pathogeny of Henoch-Schönlein nephritis remains incompletely elucidated and controlled therapeutic trials are still needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11795675     DOI: 10.1007/s004310100841

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

Review 1.  Dermacase. Henoch-Schönlein purpura.

Authors:  Anatoli Freiman
Journal:  Can Fam Physician       Date:  2005-04       Impact factor: 3.275

2.  Histological prognostic factors in children with Henoch-Schönlein purpura nephritis.

Authors:  Jean-Daniel Delbet; Guillaume Geslain; Martin Auger; Julien Hogan; Rémi Salomon; Michel Peuchmaur; Georges Deschênes; David Buob; Cyrielle Parmentier; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2019-11-06       Impact factor: 3.714

3.  Clinical outcome in children with Henoch-Schönlein nephritis.

Authors:  Sevgi Mir; Onder Yavascan; Fatma Mutlubas; Betul Yeniay; Ferah Sonmez
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

4.  Imbalance towards Th1 pathway predominance in purpura nephritis with proteinuria.

Authors:  Kazushi Tsuruga; Shojiro Watanabe; Eishin Oki; Tomomi Aizawa-Yashiro; Hidemi Yoshida; Tadaatsu Imaizumi; Etsuro Ito; Hiroshi Tanaka
Journal:  Pediatr Nephrol       Date:  2011-09-16       Impact factor: 3.714

5.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Authors:  Hiroshi Tanaka; Koichi Suzuki; Tohru Nakahata; Etsuro Ito; Shinobu Waga
Journal:  Pediatr Nephrol       Date:  2003-03-28       Impact factor: 3.714

6.  Henoch Schönlein nephritis: clinical findings related to renal function and morphology.

Authors:  Stella F Edström Halling; Magnus P Söderberg; Ulla B Berg
Journal:  Pediatr Nephrol       Date:  2004-10-22       Impact factor: 3.714

7.  Intravenous dexamethasone followed by oral prednisolone versus oral prednisolone in the treatment of childhood Henoch-Schönlein purpura.

Authors:  Jae Il Shin; Su Jin Lee; Jae Seung Lee; Kee Hyuck Kim
Journal:  Rheumatol Int       Date:  2010-05-13       Impact factor: 2.631

8.  Analysis of a uteroglobin gene polymorphism in childhood Henoch-Schonlein purpura.

Authors:  Eli M Eisenstein; Moonsuk Choi
Journal:  Pediatr Nephrol       Date:  2006-04-20       Impact factor: 3.714

9.  Renal biopsy 2-9 years after Henoch Schönlein purpura.

Authors:  Carmen Algoet; Willem Proesmans
Journal:  Pediatr Nephrol       Date:  2003-04-03       Impact factor: 3.714

10.  Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.

Authors:  Stella Edström Halling; Magnus P Söderberg; Ulla B Berg
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.